Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter, randomized, open-label, parallel-group study of albiglutide versus insulin glargine in type 2 diabetes mellitus
2008-007661-24Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2009
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of albiglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GSK. Primary endpoint: Change in HbA1c from baseline to week 52. Started Mar 2009; status: completed.
02
Drugs
albiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-007661-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007661-24.